The U.S. House Oversight and Reform Committee issued a blistering report late last week accusing brand pharmaceutical manufacturers of systematically jacking up prices on their drugs in the United States.
Pharmaceutical Research and Manufacturers of America (PhRMA) called it a “misleading report [that] fails to address abusive practices by insurance companies and middlemen.” The committee’s Republican minority issued a short opposing report on pharmacy benefit managers’ (PBM) role in rising prescription drug costs.
The U.S. House Oversight and Reform Committee issued a blistering report late last week accusing brand pharmaceutical manufacturers of systematically jacking up prices on their drugs in the United States.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
